Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 13;7(12):832-840.
doi: 10.1002/jgh3.12999. eCollection 2023 Dec.

Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta-analysis

Vikash Jaiswal  1 , Maha Hameed  2 , Sidra Naz  3 , Poulami Roy  4 , Novonil Deb  4 , Janta Ukrani  5 , Gautham Varun Krishna Mohan  6 , Amira M Taha  7 , Helen Huang  8 , Vikash Kumar  9 , Bhavyakumar Vachhani  9 , Abdelrahman M Attia  10 , Supti D Nath  11 , Mostafa A Solimn  10 , Dattatreya Mukherjee  12
Affiliations
Review

Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta-analysis

Vikash Jaiswal et al. JGH Open. .

Abstract

Background and aim: Molecular-targeted agents such as lenvatinib and sorafenib have been approved to treat hepatocellular carcinoma (HCC). However, the choice between these two agents in the primary treatment for advanced HCC is still under debate with conflicting results. We sought to evaluate the efficacy of lenvatinib and sorafenib in patients with HCC.

Methods: We performed a systematic literature search using PubMed, Embase, and Scopus for relevant articles from inception until February 10, 2023. The primary outcome of this meta-analysis was overall survival (OS). The secondary outcomes were progression-free survival (PFS), time to progression, objective response rate (ORR), and disease control rate (DCR).

Results: A total of 13 studies with 3705 patients (1635 on lenvatinib and 2070 on sorafenib) were included in our analysis. The mean age of the patients in both groups was comparable (66.81 vs 65.9 years). Pooled analysis of primary outcomes showed that, compared with sorafenib, lenvatinib was associated with significantly better OS in patients treated with these drugs (HR 0.82, 95% CI: 0.69-0.97, P = 0.02). Pooled analysis also showed that PFS (HR 0.67, 95% CI: 0.57-0.78, P < 0.00001) and time to progression (HR 0.49, 95% CI: 0.31-0.79; P = 0.004) were significantly better in the lenvatinib group compared to the sorafenib group. It also showed that the lenvatinib group had significantly better ORR (odds ratio [OR] 5.43, 95% CI: 3.71-7.97; P < 0.00001) and DCR (OR 2.35, 95% CI: 1.75-3.16; P < 00001) than the sorafenib group.

Conclusion: Our study shows that lenvatinib is superior to sorafenib regarding OS and PFS in patients with advanced HCC.

Keywords: hepatocellular carcinoma; lenvatinib; mortality; sorafenib.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Meta‐analysis showing the forest plot of primary outcome: Overall survival.
Figure 2
Figure 2
Forest plot of secondary outcomes: (a) progression‐free survival, and (b) time to progression.
Figure 3
Figure 3
Forest plot of secondary outcomes: (a) objective response rate, and (b) disease control rate.
Figure 4
Figure 4
Central illustration showing the clinical findings among hepatocellular carcinoma patients on lenvatinib and sorafenib.
Figure 5
Figure 5
Mechanism of action for lenvatinib and sorafenib on tumor angiogenesis, cell proliferation, and survival in hepatocellular carcinoma.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mittal S, El‐Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J. Clin. Gastroenterol. 2013; 47: S2–S6. - PMC - PubMed
    1. Petrick JL, Florio AA, Znaor A et al. International trends in hepatocellular carcinoma incidence, 1978‐2012. Int. J. Cancer. 2020; 147: 317–330. - PMC - PubMed
    1. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017; 96: e5904. - PMC - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68: 394–424. - PubMed
    1. Finn RS. Emerging targeted strategies in advanced hepatocellular carcinoma. Semin. Liver Dis. 2013; 33: S11–S19. - PubMed